AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23948351 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib (250 mg, once per day)
Number of subjects: 400
Study 23948351 — intervention group
Group type: EXPERIMENTAL
Intervention: Icotinib
Number of subjects: 400
Study 22168530 — intervention group
Group type: EXPERIMENTAL
Intervention: My Asthma Portal (MAP) and usual care
Number of subjects: 80
Study 22168530 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 80
Study 18950332 — intervention group
Group type: COMPARATOR
Intervention: GA group: general anesthesia with sevoflurane
Number of subjects: 30
Study 18950332 — intervention group
Group type: EXPERIMENTAL
Intervention: GA+CP group: GA with sevoflurane, combined with caudal anesthesia of plain Bupivacaine (1.25 ml x kg(‐1) of 0.2%)
Number of subjects: 30
Study 18950332 — intervention group
Group type: EXPERIMENTAL
Intervention: GA+CA group: sevoflurane GA combined with caudal anesthesia of epinephrine‐added Bupivacaine (1.25 ml x kg(‐1) of 0.2% Bupivacaine plus 1/200,000 epinephrine)
Number of subjects: 30
Study 17163246 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenspiride (stage 1 COPD)
Number of subjects: 58
Study 17163246 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenspiride (stage 2 COPD)
Number of subjects: 58
Study 17163246 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenspiride (exacerbations of COPD)
Number of subjects: 58
Study 17163246 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone (stage 2 COPD)
Number of subjects: 58
Study 17163246 — intervention group
Group type: COMPARATOR
Intervention: Control groups (stages 1 and 2 COPD)
Number of subjects: 58
Study 14707438 — intervention group
Group type: EXPERIMENTAL
Intervention: Brazilian version of the Recent Life Events Interview
Number of subjects: 41
Study 9674663 — intervention group
Group type: EXPERIMENTAL
Intervention: Seattle Angina Questionnaire (SAQ)
Number of subjects: 107
Study 9674663 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Form Health Survey (SF-36)
Number of subjects: 107
Study 9674663 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life Index-Cardiac Version III (QLI)
Number of subjects: 107
Study 9674663 — intervention group
Group type: EXPERIMENTAL
Intervention: Canadian Cardiovascular Society Classification (CCSC)
Number of subjects: 107
Study 7640102 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol 350 mg I/ml
Number of subjects: 0
Study 7640102 — intervention group
Group type: COMPARATOR
Intervention: iopamidol 370 mg I/ml
Number of subjects: 0
Study 2769441 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure wristbands for five days
Number of subjects: 16
Study 2769441 — intervention group
Group type: COMPARATOR
Intervention: No therapy for five days followed by acupressure wristbands for five days
Number of subjects: 16
Study 1071672 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 10
Study 1071672 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 10
Study 27171130 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-scleral lens with low apical clearance (100 to 200 µm)
Number of subjects: 11
Study 27171130 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-scleral lens with medium apical clearance (200 to 300 µm)
Number of subjects: 11
Study 27171130 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-scleral lens with high apical clearance (greater than 300 µm)
Number of subjects: 11
Study 27171130 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller diameter lenses
Number of subjects: 11
Study 27171130 — intervention group
Group type: EXPERIMENTAL
Intervention: Central corneal thickness measured with OCT
Number of subjects: 11
Study 27171130 — intervention group
Group type: EXPERIMENTAL
Intervention: Central corneal thickness measured with Pentacam
Number of subjects: 11
Study 24140326 — intervention group
Group type: COMPARATOR
Intervention: Capsicum (2g/cow daily)
Number of subjects: 8
Study 24140326 — intervention group
Group type: COMPARATOR
Intervention: Garlic (2g/cow daily)
Number of subjects: 8
Study 24140326 — intervention group
Group type: COMPARATOR
Intervention: All phytonutrients (curcumin, garlic, capsicum)
Number of subjects: 8
Study 24140326 — intervention group
Group type: COMPARATOR
Intervention: Phytonutrients (all treatments)
Number of subjects: 8
Study 20875186 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-milk protein solution (40 g/l carbohydrate, 25 g/l milk protein)
Number of subjects: 8
Study 20875186 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate solution (65 g/l carbohydrate)
Number of subjects: 8
Study 19017760 — intervention group
Group type: EXPERIMENTAL
Intervention: 54 mg/d genistein for 24 weeks
Number of subjects: 50
Study 19017760 — intervention group
Group type: EXPERIMENTAL
Intervention: 54 mg/d genistein for 24 weeks (normoinsulinemic subgroup)
Number of subjects: 50
Study 19017760 — intervention group
Group type: EXPERIMENTAL
Intervention: 54 mg/d genistein for 24 weeks (hyperinsulinemic subgroup)
Number of subjects: 50
Study 19017760 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 24 weeks
Number of subjects: 50
Study 17712643 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 50
Study 17712643 — intervention group
Group type: COMPARATOR
Intervention: Double pigtail stent insertion
Number of subjects: 50
Study 15104196 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal triamcinolone acetonide (220 microg once daily) for 6 weeks
Number of subjects: 32
Study 15104196 — intervention group
Group type: COMPARATOR
Intervention: No intranasal corticosteroid treatment
Number of subjects: 32
Study 11278161 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenics (deficit and non-deficit)
Number of subjects: 105
Study 11278161 — intervention group
Group type: EXPERIMENTAL
Intervention: Deficit patients
Number of subjects: 105
Study 11278161 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenics
Number of subjects: 105
Study 11278161 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 105
Study 9848301 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin (3.75 mg IM)
Number of subjects: 57
Study 9848301 — intervention group
Group type: COMPARATOR
Intervention: Control (no triptorelin)
Number of subjects: 57
Study 8006332 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline instillation (100 mg/ml, range: 1-4 ml)
Number of subjects: 37
Study 8006332 — intervention group
Group type: COMPARATOR
Intervention: Repeated needle aspiration
Number of subjects: 37
Study 1857131 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization techniques (stratification and blocking) used in the Firm System
Number of subjects: 0
Study 1857131 — intervention group
Group type: EXPERIMENTAL
Intervention: Prestudy evaluations of equivalence
Number of subjects: 0
Study 1857131 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigilant system maintenance programs
Number of subjects: 0
Study 901705 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (H2-receptor antagonist)
Number of subjects: 0
Study 901705 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine + Chlorpheniramine (H1-receptor antagonist)
Number of subjects: 0
Study 901705 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 0
Study 31410963 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental arm (anticancer therapies)
Number of subjects: 6
Study 31410963 — intervention group
Group type: COMPARATOR
Intervention: Control arm (anticancer therapies)
Number of subjects: 6
Study 31410963 — intervention group
Group type: EXPERIMENTAL
Intervention: Principal stratification
Number of subjects: 6
Study 27879982 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance band exercises (conducted three times per week in 40-minute sessions, volunteer-led for the first 6 months followed by DVD-guided for the next 9 months)
Number of subjects: 150
Study 27879982 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 150
Study 26591403 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (Citazol®)
Number of subjects: 30
Study 26591403 — intervention group
Group type: COMPARATOR
Intervention: Cilostazol (Pletaal®)
Number of subjects: 30
Study 23927387 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel releasing intrauterine system (LNG-IUS)
Number of subjects: 0
Study 23927387 — intervention group
Group type: COMPARATOR
Intervention: Endometrial ablation (Novasure)
Number of subjects: 0
Study 22321501 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrysof toric IOL (T3, T4, T5)
Number of subjects: 80
Study 22321501 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrysof toric IOL (T5b)
Number of subjects: 80
Study 22321501 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrysof toric IOL
Number of subjects: 80
Study 22321501 — intervention group
Group type: COMPARATOR
Intervention: Control group (Acrysof Natural IOL, 65 eyes, 45 patients)
Number of subjects: 80
Study 19862937 — intervention group
Group type: EXPERIMENTAL
Intervention: A-444C polymorphism in the LTC4S gene
Number of subjects: 275
Study 19862937 — intervention group
Group type: COMPARATOR
Intervention: Nonallergic controls
Number of subjects: 275
Study 16953985 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg E2V/2.5 mg MPA daily (1 + 2.5 group)
Number of subjects: 419
Study 16953985 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg E2V/5 mg MPA daily (1 + 5 group)
Number of subjects: 419
Study 16953985 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg E2V/2.5 mg MPA daily (2 + 2.5 group)
Number of subjects: 419
Study 16953985 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg E2V/5 mg MPA daily (2 + 5 group)
Number of subjects: 419
Study 16953985 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of ccHRT
Number of subjects: 419
Study 16987360 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol (1 g every 6 hours)
Number of subjects: 48
Study 16987360 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal paracetamol (1 g every 6 hours)
Number of subjects: 48
Study 14528577 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinaesthetic mobilization
Number of subjects: 104
Study 14528577 — intervention group
Group type: COMPARATOR
Intervention: Standard mobilization
Number of subjects: 104
Study 10592405 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotrexin (combination of isotretinoin 0.05% and erythromycin 2%)
Number of subjects: 0
Study 10592405 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin (0.05%)
Number of subjects: 0
Study 10592405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7491888 — intervention group
Group type: EXPERIMENTAL
Intervention: OB diet (oat bran bread, 12.5 g beta-glucan/d)
Number of subjects: 9
Study 7491888 — intervention group
Group type: EXPERIMENTAL
Intervention: OBE diet (oat bran with beta-glucanase, 3.8 g beta-glucan/d)
Number of subjects: 9
Study 7491888 — intervention group
Group type: EXPERIMENTAL
Intervention: B diet (barley, 13.0 g beta-glucan/d)
Number of subjects: 9
Study 7491888 — intervention group
Group type: EXPERIMENTAL
Intervention: W diet (wheat flour, 1.2 g beta-glucan/d)
Number of subjects: 9
Study 2344168 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% mercuric oxide ophthalmic ointment, treated twice daily for 7 days
Number of subjects: 39
Study 2344168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 7002691 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (2 mg bolus followed by 0.1 mg/Kg/die for the next 48 hours in continuous i.v. infusion)
Number of subjects: 42
Study 7002691 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 31690980 — intervention group
Group type: EXPERIMENTAL
Intervention: Eluvia Drug-Eluting Vascular Stent System
Number of subjects: 84
Study 31690980 — intervention group
Group type: COMPARATOR
Intervention: Zilver PTX Drug-Eluting Peripheral Stent
Number of subjects: 84
Study 31395113 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of oral habits
Number of subjects: 830
Study 31395113 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth-breathing
Number of subjects: 830
Study 31395113 — intervention group
Group type: EXPERIMENTAL
Intervention: Biting objects
Number of subjects: 830
Study 31395113 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-inflicting habits
Number of subjects: 830
Study 31395113 — intervention group
Group type: EXPERIMENTAL
Intervention: Lip sucking
Number of subjects: 830
Study 31395113 — intervention group
Group type: EXPERIMENTAL
Intervention: Lip-biting habits
Number of subjects: 830
Study 28946582 — intervention group
Group type: EXPERIMENTAL
Intervention: Shaker exercise and conventional dysphagia therapy
Number of subjects: 32
Study 28946582 — intervention group
Group type: COMPARATOR
Intervention: Conventional dysphagia therapy
Number of subjects: 32
Study 25622199 — intervention group
Group type: EXPERIMENTAL
Intervention: SS plus sertraline
Number of subjects: 69
Study 25622199 — intervention group
Group type: COMPARATOR
Intervention: SS plus placebo
Number of subjects: 69
Study 23710672 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing, and one or more of periodontal surgery, systemically administered amoxicillin + metronidazole or local tetracycline at pockets ≥5 mm
Number of subjects: 178
Study 21893583 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 652
Study 21893583 — intervention group
Group type: COMPARATOR
Intervention: Placebo (+MTX)
Number of subjects: 652
Study 19401015 — intervention group
Group type: EXPERIMENTAL
Intervention: Open access HSG
Number of subjects: 670
Study 19401015 — intervention group
Group type: COMPARATOR
Intervention: Usual management (Control)
Number of subjects: 670
Study 17197435 — intervention group
Group type: EXPERIMENTAL
Intervention: XPD Gln751C/Asp312G ('D') haplotype
Number of subjects: 100
Study 17197435 — intervention group
Group type: EXPERIMENTAL
Intervention: ERCC1 polymorphisms
Number of subjects: 100
Study 17197435 — intervention group
Group type: EXPERIMENTAL
Intervention: XRCC3 241Met variant
Number of subjects: 100
Study 15315566 — intervention group
Group type: EXPERIMENTAL
Intervention: In-out catheterization
Number of subjects: 1448
Study 15315566 — intervention group
Group type: COMPARATOR
Intervention: Indwelling catheterization for 24 hours
Number of subjects: 1448
Study 11395033 — intervention group
Group type: EXPERIMENTAL
Intervention: Apo A-IV infusion with deuterated leucine over a 15 h time period with hourly feeding; TRL separated by ultracentrifugation; apo A-IV isolated by immunoprecipitation and/or SDS-PAGE.
Number of subjects: 19
Study 11395033 — intervention group
Group type: EXPERIMENTAL
Intervention: Apo A-IV infusion with deuterated leucine; TRL and plasma apo A-IV residence times (RT) and transport rates (TR) measured.
Number of subjects: 19
Study 11395033 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of TRL apo A-IV concentrations and TR; TRL apo A-IV pool size and TRL cholesterol levels.
Number of subjects: 19
Study 9426382 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO+ (50g carbohydrates, 200 micrograms chromium-picolinate, 20g soluble fibre, 100 mg caffeine)
Number of subjects: 33
Study 9426382 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO (50g plain carbohydrates)
Number of subjects: 33
Study 9426382 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 33
Study 9426382 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects (combined analysis)
Number of subjects: 33
Study 9426382 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium intake
Number of subjects: 33
Study 8515824 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam
Number of subjects: 12
Study 8515824 — intervention group
Group type: EXPERIMENTAL
Intervention: Kava
Number of subjects: 12
Study 3574137 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame in solution (3 g)
Number of subjects: 10
Study 3574137 — intervention group
Group type: COMPARATOR
Intervention: Aspartame in capsules (3 g)
Number of subjects: 10
Study 30798084 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy continuation (CT-CONT)
Number of subjects: 67
Study 30798084 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy discontinuation (CT-DISC)
Number of subjects: 67
Study 28255557 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-task trials (walking without distraction)
Number of subjects: 195
Study 28255557 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task trials (walking while conversing on a cell phone)
Number of subjects: 195
Study 28255557 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 195
Study 28255557 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical function
Number of subjects: 195
Study 24438467 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity with BFR (50% of 1-RM with BFR)
Number of subjects: 13
Study 24438467 — intervention group
Group type: COMPARATOR
Intervention: High-intensity exercise (80% of 1-RM)
Number of subjects: 13
Study 23485955 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR (50-300 mg/day)
Number of subjects: 1752
Study 23485955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1752
Study 21256179 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-l-Carnitine (3g/day)
Number of subjects: 64
Study 21256179 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-l-Carnitine (1g/day)
Number of subjects: 64
Study 21256179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 19551353 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyclosporine ophthalmic emulsion 0.05%
Number of subjects: 37
Study 19551353 — intervention group
Group type: COMPARATOR
Intervention: Artificial tear solution
Number of subjects: 37
Study 16687452 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 109
Study 16687452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 15295720 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg daily for one month
Number of subjects: 24
Study 15295720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12795493 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 108
Study 12795493 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 108
Study 12795493 — intervention group
Group type: COMPARATOR
Intervention: Conventional antipsychotic medications
Number of subjects: 108
Study 9665097 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong black tea (1600 mL/d)
Number of subjects: 15
Study 9665097 — intervention group
Group type: EXPERIMENTAL
Intervention: Fried onions (129 g/d)
Number of subjects: 15
Study 9665097 — intervention group
Group type: EXPERIMENTAL
Intervention: Fried onions (129 g/d) repeated treatment
Number of subjects: 15
Study 7793048 — intervention group
Group type: EXPERIMENTAL
Intervention: X-ray computer-aided tomography (CAT) with filling of the stomach with liquid
Number of subjects: 134
Study 7793048 — intervention group
Group type: EXPERIMENTAL
Intervention: X-ray computer-aided tomography (CAT) with pneumoscanning of the stomach
Number of subjects: 134
Study 7793048 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubal scanning of the stomach
Number of subjects: 134
Study 7793048 — intervention group
Group type: COMPARATOR
Intervention: Axial CAT of individual portions of the stomach
Number of subjects: 134
Study 2572494 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg etizolam
Number of subjects: 45
Study 2572494 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg alprazolam
Number of subjects: 45
Study 2572494 — intervention group
Group type: COMPARATOR
Intervention: 3 mg bromazepam
Number of subjects: 45
Study 1098449 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 20
Study 1098449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31621189 — intervention group
Group type: EXPERIMENTAL
Intervention: VYC-12 injectable gel
Number of subjects: 131
Study 30197226 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue function and bite force
Number of subjects: 245
Study 29104904 — intervention group
Group type: EXPERIMENTAL
Intervention: Decentralised care plus structured support visits by trained community health workers (intervention group) for 18 months.
Number of subjects: 334
Study 29104904 — intervention group
Group type: COMPARATOR
Intervention: Decentralised primary health-care clinic-based HIV care (control group) for 18 months.
Number of subjects: 334
Study 25724569 — intervention group
Group type: EXPERIMENTAL
Intervention: Bdiet (high-energy breakfast, 2,946 kJ; lunch, 2,523 kJ; dinner, 858 kJ)
Number of subjects: 18
Study 25724569 — intervention group
Group type: EXPERIMENTAL
Intervention: Bdiet
Number of subjects: 18
Study 25724569 — intervention group
Group type: COMPARATOR
Intervention: Ddiet (high-energy dinner, 2,946 kJ; lunch, 2,523 kJ; breakfast, 858 kJ)
Number of subjects: 18
Study 23820423 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral laparoscopic ovarian drilling (ULOD) with thermal doses adjusted to the volume of the right ovary (60 J/cm³)
Number of subjects: 96
Study 23820423 — intervention group
Group type: COMPARATOR
Intervention: Bilateral laparoscopic ovarian drilling (BLOD) with fixed doses of 600 J per ovary
Number of subjects: 96
Study 23820423 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral laparoscopic ovarian drilling (ULOD)
Number of subjects: 96
Study 23820423 — intervention group
Group type: COMPARATOR
Intervention: Bilateral laparoscopic ovarian drilling (BLOD)
Number of subjects: 96
Study 21685487 — intervention group
Group type: EXPERIMENTAL
Intervention: etomidate
Number of subjects: 100
Study 21685487 — intervention group
Group type: COMPARATOR
Intervention: propofol
Number of subjects: 100
Study 19960974 — intervention group
Group type: EXPERIMENTAL
Intervention: Bailing Capsule (BC) and benazepril
Number of subjects: 60
Study 19960974 — intervention group
Group type: COMPARATOR
Intervention: Benazepril alone (Control)
Number of subjects: 60
Study 16520478 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal medicine interventions
Number of subjects: 16
Study 16520478 — intervention group
Group type: EXPERIMENTAL
Intervention: Context-specific elaborations of CONSORT checklist items
Number of subjects: 16
Study 16520478 — intervention group
Group type: EXPERIMENTAL
Intervention: Item 4 concerning herbal medicine intervention
Number of subjects: 16